Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
5.44
+0.04 (0.74%)
Jul 29, 2026, 1:44 PM EDT - Market open
Verrica Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 20.6 | 30.15 | 46.33 | 69.55 | 34.27 | 15.75 |
Short-Term Investments | - | - | - | - | - | 54.6 |
Cash & Short-Term Investments | 20.6 | 30.15 | 46.33 | 69.55 | 34.27 | 70.35 |
Cash Growth | -30.39% | -34.93% | -33.38% | 102.92% | -51.29% | 7.46% |
Accounts Receivable | 7.81 | 5.4 | 0.08 | 4.42 | 0.49 | - |
Inventory | 1.97 | 2.24 | 2.46 | 1.02 | - | - |
Other Current Assets | 3.74 | 4.76 | 2.31 | 2.55 | 4.36 | 3.97 |
Total Current Assets | 34.13 | 42.54 | 51.18 | 77.53 | 39.12 | 74.33 |
Net Property, Plant & Equipment | 1.66 | 1.86 | 2.58 | 3.62 | 5.33 | 5.5 |
Other Long-Term Assets | 2.99 | 2.73 | 0.38 | 0.45 | 0.28 | 0.3 |
Total Assets | 38.79 | 47.13 | 54.13 | 81.6 | 44.72 | 80.13 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 2.19 | 2.07 | 1.9 | 2.46 | 0.51 | 0.85 |
Accrued Expenses | 12.25 | 12.84 | 13.51 | 13.86 | 2.66 | 3.27 |
Current Portion of Long-Term Debt | - | - | 12.94 | - | - | 41.69 |
Current Portion of Leases | 0.74 | 0.75 | 0.67 | 0.7 | 0.3 | 0.25 |
Unearned Revenue | 1.03 | 0.78 | - | - | - | - |
Total Current Liabilities | 16.22 | 16.44 | 29.01 | 17.02 | 3.46 | 46.06 |
Long-Term Debt | - | - | 30.98 | 42.87 | - | - |
Long-Term Leases | 0.7 | 0.89 | 1.35 | 1.94 | 1.23 | 1.47 |
Other Long-Term Liabilities | 5.81 | 5.07 | 2.65 | - | - | - |
Total Long-Term Liabilities | 6.51 | 5.95 | 34.98 | 44.81 | 1.23 | 1.47 |
Total Liabilities | 22.73 | 22.39 | 63.99 | 61.83 | 4.69 | 47.52 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-in Capital | 350.65 | 349.65 | 297.17 | 250.21 | 203.48 | 171.6 |
Accumulated Other Comprehensive Income | - | - | - | - | - | -0.03 |
Retained Earnings | -334.6 | -324.91 | -307.03 | -230.45 | -163.45 | -138.97 |
Shareholders' Equity | 16.06 | 24.74 | -9.86 | 19.76 | 40.03 | 32.61 |
Total Liabilities & Equity | 38.79 | 47.13 | 54.13 | 81.6 | 44.72 | 80.13 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.44 | 1.63 | 45.94 | 45.51 | 1.53 | 43.41 |
Net Cash (Debt) | 19.16 | 28.52 | 0.39 | 24.04 | 32.75 | 26.95 |
Net Cash Growth | - | 7211.79% | -98.38% | -26.60% | 21.53% | -4.67% |
Net Cash Per Share | 1.41 | 2.68 | 0.07 | 5.30 | 9.59 | 9.96 |
Book Value | 16.06 | 24.74 | -9.86 | 19.76 | 40.03 | 32.61 |
Book Value Per Share | 1.18 | 2.32 | -1.90 | 4.36 | 11.72 | 12.06 |
Tangible Book Value | 16.06 | 24.74 | -9.86 | 19.76 | 40.03 | 32.61 |
Tangible Book Value Per Share | 1.18 | 2.32 | -1.90 | 4.36 | 11.72 | 12.06 |